Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)

Parkinson's Disease Clinical Trial

Official title:

Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT04536857
• Other study ID #: 2020 Provisional Audit No.1004
• Status: Suspended
• Start date: October 1, 2024
• Est. completion date: December 30, 2025

Study information

• Verified date: September 2023
• Source: Huashan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The study will investigate the biomarker of a-synuclein aggregate in CSF detected by protein misfolding cyclic amplification (PMCA) and its sensitivity and specificity in diagnosing Parkinson's disease at H-Y stage I and disease duration less than 1 year, compared with that from age-matched controls without neurodegeneration, those with Multiple System Atrophy (MSA) as a disease control with a-synucleinopathy, and those with Progressive Supranuclear Palsy (PSP) as a control with non-a-synucleinopathy neurodegeneration.

Description:

This will be an observational study aiming to develop the protein misfolding cyclic amplification (PMCA) technology that detects minute amounts of αSyn aggregates circulating in cerebrospinal fluid (CSF) as a novel assay with high sensitivity and specificity for the early diagnosis of PD. To achieve this goal, we will apply the PMCA to detect the αSyn aggregates in the CSF samples acquired from a discovery cohort that consist of well-characterized early PD patients (disease duration ≤1 year and Hoehn and Yahr Stage I, and DAT-PET and FDG-PET meet the imaging features of PD, n=75) and gender, age-matched healthy controls (n=38). Furthermore, we will confirm the findings in a separate confirmatory cohort with well-characterized early PD patients (disease duration ≤1 year and Hoehn and Yahr Stage I, and DAT-PET and FDG-PET meet the imaging features of PD, n=75), early multiple system atrophy (MSA) patients (disease duration ≤1 year, n=38), early progressive supranuclear palsy (PSP) patients (disease duration ≤1 year, n=38) and age-matched healthy controls (n=38). The sensitivity, specificity, positive predictive value, negative predictive value, and area under curve of the PMCA for the early diagnosis of PD will be calculated in the discovery cohort and be confirmed in the confirmatory cohort, respectively. In addition, the clinical characteristics, including motor and nonmotor symptoms of early PD, MSA and PSP patients in the two cohort will be comprehensively assessed at baseline and during followed-up. To assess the value of the PMCA technology in the evaluation of the disease severity and progress, we will perform the partial correlation analysis between clinical features of early PD patients and the PMCA T50 defined as the time needed to reach 50% of the maximum aggregation. Misfolded αSyn aggregates have the potential to serve as a biomarker for early PD. The PMCA technology could detect small quantities of misfolded αSyn aggregates by taking advantage of their ability to nucleate further aggregation, enabling a very high amplification of the signal. This study examines the effectiveness of using the PMCA as a novel technique for discriminating early PD from gender, age-matched healthy controls and other early parkinsonian disorders (MSA, PSP) by detecting small misfolded αSyn aggregates in CSF.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 302
• Est. completion date: December 30, 2025
• Est. primary completion date: December 30, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 75 Years

Eligibility

For early PD patients

Inclusion criteria:

• Clinical diagnosis of "probable PD" by two neurologists specializing in movement disorders according to the International Parkinson and Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD (2015);
• Age 50-75, disease duration is less than 1 year, and Hoehn & Yahr Stage I;
• the dopamine reuptake transporter (DAT) is significantly reduced in striatum on PET imaging;
• Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with Parkinson's disease-related pattern (PDRP), with FDG hypermetabolism being in basal ganglia and cerebellum;
• Good response to anti-PD medications;
• Ability of completing questionnaires;
• Ability of providing informed consent;
• Willingness of being assessed by neurologists during off-medication state defined as discontinuing anti-PD medications for at least 12 hours before assessment.

Exclusion criteria:

• Secondary parkinsonism (ie. drug induced);
• Atypical parkinsonisms like MSA or PSP etc;
• Presence of any item in 10 red flags of the MDS Clinical Diagnostic Criteria for PD (2015) in the comprehensive assessments during follow-up;
• History of being diagnosed as any cancer within 5 years;
• Presence of any condition risking the procedure of performing lumbar puncture (LP);
• Pregnancy;
• Inability to comply with study procedures. For early MSA patients

Inclusion criteria:

• Clinical diagnosis of "probable MSA" by two neurologists specializing in movement disorders according to the International Parkinson and Movement Disorder Society (MDS) second consensus criteria for MSA (2019);
• Age 50-75, and disease duration is less than 1 year;
• Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with MSA related pattern;
• Ability of completing questionnaires;
• Ability of providing informed consent;
• Willingness of being assessed by neurologists during off-medication state defined as discontinuing anti-PD medications for at least 12 hours before assessment.

Exclusion criteria:

• Secondary parkinsonism (ie. drug induced);
• History of being diagnosed as any cancer within 5 years;
• Presence of any condition risking the procedure of performing lumbar puncture (LP);
• Pregnancy;
• Inability to comply with study procedures. For PSP patients

Inclusion criteria:

• Clinical diagnosis of "probable PSP" by two neurologists specializing in movement disorders according to MDS Clinical Diagnostic Criteria for PSP (2017);
• Age 50-75, disease duration is less than 1 year;
• Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with PSP related pattern;
• Ability of completing questionnaires;
• Ability of providing informed consent;
• Willingness of being assessed by neurologists during off-medication state defined as discontinuing anti-PD medications for at least 12 hours before assessment.

Exclusion criteria:

• Secondary parkinsonism (ie. drug induced);
• History of being diagnosed as any cancer within 5 years;
• Presence of any condition risking the procedure of performing lumbar puncture (LP);
• Pregnancy;
• Inability to comply with study procedures. For controls without diagnosis of neurodegenerative disorders

Inclusion criteria:

• Age 50-75;
• No history of neurodegenerative disease of the central nervous system;
• No history of infective disease of the central system;
• Ability of completing questionnaires;
• Ability of providing informed consent.

Exclusion criteria:

• With prodromal symptoms of PD, such as rapid eye movement sleep behavior disorder (RBD);
• History of being diagnosed as any cancer within 5 years;
• Presence of any condition increasing the risk of the procedure of performing lumbar puncture (LP);
• Pregnancy;
• Inability to comply with study procedures.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Other:
• Biomarker assay
Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.

Locations

Country	Name	City	State
China	Huashan Hospital Affiliated to Fudan University	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Huashan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The area under curve of the PMCA for the early diagnosis of PD	The area under curve is used to show the ability of the a-syn-PMCA to diagnose early PD. The value of area under curve is higher, then the ability of the a-syn-PMCA to diagnose early PD is stronger.	two years
Secondary	The correlation between the PMCA T50 and MDS-UPDRS III score at baseline in PD patients	PMCA T50 is the time needed to reach 50% of the maximum aggregation. The motor symptoms of PD patients will be assessed using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS- III).	two years
Secondary	The correlation between PMCA T50 and subregional DAT in striatum in PD patients	PMCA T50 is the time needed to reach 50% of the maximum aggregation. The DAT uptake value (caudate, anterior putamen and/or posterior putamen) will be quantified using DAT-PET.	two years
Secondary	The correlation between PMCA T50 and PDRP expression value in PD patients	PMCA T50 is the time needed to reach 50% of the maximum aggregation. The Parkinson's disease-related pattern (PDRP) expression value will be quantified by using FDG-PET.	two years
Secondary	The correlation between PMCA T50 and the change of MDS-UPDRS III score between the baseline and the follow-up	PMCA T50 is the time needed to reach 50% of the maximum aggregation. The change of MDS-UPDRS III score is the difference of that between the baseline and the follow-up.	two years
Secondary	The sensitivity	The sensitivity is used to show the ability of the a-syn-PMCA to diagnose early PD patients, and is represented by true positive/ (true positive +false negative).	two years
Secondary	The specificity	The specificity is used to show the ability of the a-syn-PMCA to avoid false early PD patients and rule out early PD patients, and is represented by true negative/ (false positive + true negative).	two years
Secondary	The positive predictive value	The positive predictive value is used to show the ability of the a-syn-PMCA to correctly label early PD patients who test positive, and is represented by true positive / (true positive + false positive).	two years
Secondary	The negative predictive value	The negative predictive value is used to show the ability of the a-syn-PMCA to correctly label people who test negative, and is represented by true negative / (false negative + true negative).	two years